Compare C.H. Robinson Worldwide, Inc. (CHRW) vs State Street SPDR S&P Biotech ETF (XBI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
C.H. Robinson Worldwide, Inc. vs State Street SPDR S&P Biotech ETF — how do they compare? C.H. Robinson Worldwide, Inc. trades at $197.66 (market cap $23.53B), while State Street SPDR S&P Biotech ETF trades at $156.15. The key difference: C.H. Robinson Worldwide, Inc. pays a 1.26% dividend while State Street SPDR S&P Biotech ETF pays none. Which is the better fit depends on your goals.
| CHRW | XBI | |
|---|---|---|
Market Cap | $23.53B | — |
Sector | Industrials | Broad Market / Factor |
52-Week High | $200.59 | $164.28 |
52-Week Low | $96.82 | $85.16 |
Enterprise Value | $25.02B | — |
Dividend Yield | 1.26% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CHRW trades at $196.50, up 1.55% today, with a bullish technical signal from moving averages but overbought RSI readings. The company reported strong earnings beats in recent quarters, with Q2 2026 results pending. Revenue declined to $16.23B in 2025, but net income margin improved to 3.7%. Recent acquisitions like DeSpir Logistics and AI-driven supply chain innovations highlight growth initiatives. Analyst consensus is mixed with a $199.38 price target, slightly above current levels.
Outlook remains cautiously optimistic given earnings momentum and operational efficiency gains, though high valuation ratios (P/E 39.78) and industry freight challenges pose risks. The stock's proximity to resistance at $199 suggests near-term consolidation potential, with long-term upside dependent on execution of tech investments and market share expansion.
XBI trades at $155.34, down 2.32% on the day, but maintains a bullish technical outlook with strong momentum indicators. The biotech ETF has gained significant attention after a 17% monthly surge, driven by sector rotation and M&A activity. Analyst coverage remains limited with a single hold rating, though recent news highlights biotech's strong performance amid market volatility.
The ETF offers exposure to biotech's resurgence with AI drug discovery and deal momentum as catalysts. However, high volatility and concentrated sector risk require careful position sizing. Current technical strength suggests potential for continued upside if sector momentum persists.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About C.H. Robinson Worldwide, Inc.
C.H. Robinson is a top-tier non-asset-based third-party logistics provider with a significant focus on domestic freight brokerage (57% of 2021 net revenue), which reflects mostly truck brokerage but also rail intermodal. Additionally, the firm also operates a large air and ocean forwarding division (34%), which has grown organically and via tuck-in acquisitions. The remainder of revenue consists of the European truck-brokerage division, transportation management services, and a legacy produce-sourcing operation.
Read more on CHRW →About State Street SPDR S&P Biotech ETF
XBI is an equal-weighted ETF that tracks the U.S. biotechnology segment. It provides diversified exposure to small, mid, and large-cap biotech firms involved in drug discovery and medical research, such as Moderna and Exact Sciences.
Read more on XBI →
